The Pharmaceutical Anti-Counterfeiting Technology Market Will Reach $6.5bn In 2020, A New Study Predicts

07 September 2018
Pharma

A new report by visiongain forecasts the world pharmaceutical anti-counterfeiting technology market will reach $6.5bn in 2020. That revenue prediction and others appear in Pharmaceutical Anti-Counterfeiting Technologies Market Forecast 2016-2026, published in April 2016. Visiongain is a business information publisher and consultancy in London, UK.

The analysis predicts the global pharmaceutical anti-counterfeiting technologies market will continue to grow at a CAGR of 13.6% from 2014-2020, driven by the barcode and RFID submarkets. In 2015, the barcode submarket held a higher market share than the RFID submarket. However, the RFID submarket will become the leading submarket in 2017.
Demand for the market will be fuelled by an increasing prevalence of illegal counterfeiting incidents. Pharmaceutical companies will increasingly identify the need to protect their intellectual property and brand integrity by marginalising the rise in counterfeit activity through the use of technology.
Robert King, a pharmaceutical and healthcare industry analyst in visiongain, said:
“The introduction of tougher criminal penalties for counterfeiters coupled with government involvement demanding e-pedigrees on all pharmaceutical products will help to expand the anti-counterfeiting technologies market. The increasingly global pharmaceutical supply chain will also act as a catalyst for growth in this market. China and India, for example, are among the largest exporters of pharma products; therefore growth in the anti-counterfeiting technologies market of these two big economies will boost the global market.
To implement anti-counterfeiting technologies on a global scale there must be cohesion between different national regulatory authorities. Cooperation between countries on an international level must improve – many are now working towards standardisation”.
This report investigates commercial trends and revenues of the pharmaceutical anti-counterfeiting technology market from 2016 to 2026, as well as including data from 2014/2015. This report discusses sales potentials of:

• The main submarkets of pharmaceutical anti-counterfeiting technology:
o Barcodes
o RFID
o Taggants
o Hologram/OVD
o Other

• 8 leading national markets:
o US
o Japan
o EU
o China
o Russia
o India
o Brazil
o Mexico

This report qualitatively discusses:

• 15 anti-counterfeiting technology companies (including financial information) such as:
o 3M
o Avery Dennison
o ThermoFisher
o Multi Packaging Solutions

• The current and incoming legislation on a national market scale for pharmaceutical anti-counterfeiting technology including:
o The US
o The EU
o Brazil
o Russia
o India

• Strengths, weaknesses, opportunities and threats of the pharmaceutical anti-counterfeiting market.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever